Vir Biotechnology Collaborates with NIH Vaccine Research Center to Advance the Development of mAbs Against Coronavirus

Vir Biotechnology Collaborates with NIH Vaccine Research Center to Advance the Development of mAbs Against Coronavirus

Shots:

  • Vir and NIAID will jointly identify and optimize combinations of Ab against coronaviruses, including SARS-CoV-2, SARS, and MERS along with Ab that may show effectiveness across additional types of coronaviruses
  • The collaboration allows Vir to access VRC’s research experience with coronaviruses to accelerate the development of Ab targeting the unmet medical needs of patients
  • Vir has identified several mAbs that bind to SARS-CoV-2 and were isolated from individuals who had survived a SARS infection. The company is evaluating Ab that it may be able to identify from COVID-19 survivors, can be effective as treatment and/or prophylaxis against SARS-CoV-2

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: PRNewswire